Overview

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

Status:
Completed

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

This study is for healthy participants. This study tests single dose of the research drug HSP-130 against two existing approved drugs United States - approved Neulasta and European Union-approved Neulasta.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Collaborators:

Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer

Treatments:

Lenograstim